This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
  • 00
  • 00
  • 00
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Caledon Bioscience Inc.


Caledon Biosciences is a new startup which has acquired the key assets from the shell of Liminal Biosciences, a former NASDAQ listed company which was taken private by the principal investor, Thomvest Asset Management Inc. which is the investment arm of Canada's wealthiest family and owners of Thomson Reuters. Now that the take-private has been finalized and go forward operations have been streamlined, Caledon Bioscience Inc. has been spun off, is Seed funded by Thomvest and are now in the process of seeking private, VC co-investors to help take the company through to the next value inflection points. Thomvest are not your typical biotech investors and although they have signified their willingness to participate in future financings, we are looking to expand the investor base with experienced biotech investors.

Given the recent streamlining of business operations, Caledon is as capital efficient as possible and we are able to leverage the resources of our lead program to move the others programs forward at modest cost. We are based in Montreal, Canada with operations in Cambridge, UK.

We have a pipeline of 3, small-molecule assets focused on GPCR targets implicated in inflammation, fibrosis and metabolic disease, the first of which, a selective GPR84 antagonist for NASH/NAFLD will be in the clinic in before the end of this year. Our CTA has recently been submitted. Our second asset, another selective antagonist, targets OXER1 for the treatment of eosinophilic driven disease. On this program we have selected the lead candidate and are getting ready to commence CTA enabling activity. We intend to tackle eosinophilic asthma and atopic dermatitis with this compound. Finally, we have a selective GPR40 agonist for the treatment of metabolic disease and T2D.